REYON PHARMACEUTICAL CO., LTD Early acquisition of own convertible bonds, KRW 3.0 billion of Series 3
REYON PHARMACEUTICAL CO., LTD· Material Event Report
RAI summary · Not investment advice
The company decided to acquire KRW 3.0 billion face value of Series 3 convertible bonds before maturity for about KRW 3.3 billion over the counter.
Face value acquired
KRW 3.0 billion
Key facts
- Bond type
- Series 3 bearer-type, non-rights, unguaranteed private placement convertible bond
- Bond issue date
- Oct 25, 2024
- Maturity date
- Oct 25, 2029
- Total face value
- KRW 85.0 billion
- Acquisition amount
- KRW 3.3 billionBasis: principal and interest
- Acquisition method
- Over-the-counter purchase
- Reason for acquisition
- Decision to acquire the bonds before maturity through consultation with bondholders
- Plan for acquired bonds
- To be decided later by board resolution
- Remaining bonds after acquisition
- KRW 81.0 billion
- Conversion price per share
- KRW 9,795
- % of total shares
- 1.62%
Earlier Material Event Report filings from this company
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.10.272026.10.27 | [Amended] Material Event Report | KRW 9.0 billion · 4.54% of total shares · 49.15% including outstanding bonds · changed from KRW 10.0 billion |
| 26.10.262026.10.26 | Material Event Report | KRW 950.0 million · 0.52% of total shares · handling to be decided later by the board |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist